MSH-2 and MLH-1 Protein expression in muir torre syndrome- related and sporadic sebaceous neoplasms

Puerto Rico Health Sciences Journal

Volumn 27, Issue 4, 2008, Pages 322-327

  Morales Burgos, Adisbeth ^a,c   Sánchez, Jorge L ^a   Figueroa, Luz D ^a,c   Wilfredo E De Jesus Monge ^b   Cruz Correa, Marcia R ^c   González Keelan, Carmen ^d   Nazario, Cruz María ^e  

^a Medical Sciences Campus   (Puerto Rico)

^b Department of Medicine   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d Laboratory Medicine   (Saudi Arabia)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

DNA mismatch repair; Immunohistochemistry; MSH 2; Muir torre syndrome; Sebaceous neoplasm

Indexed keywords

MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUIR TORRE SYNDROME; SEBACEOUS GLAND TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUIR-TORRE SYNDROME; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; SEBACEOUS GLAND NEOPLASMS;

EID: 61549106655     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Muir EG, Yates Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with keratoacanthomata of the face. Br J Surg 1967;54:191-195.
2. T orre D. Multiple sebaceous neoplasms of the skin. Arch Dermatol 1968;98:549-551.
3. Ackerman B, Nussen S. New Concept: Sebaceous "adenoma" is sebaceous carcinoma. Dermatopathol: Pract & Concep, 1998: p. 4.
4. Ackerman B, Nussen S. The history: Respective contributions of Muir and Torre. Dermatopathol: Practl & Concept, 1999: p. 5.
5. Schwartz R, Torre D. The Muir-Torre syndrome: A 25-year retrospect. J Am Acad Dermatol 1995;33:90-103.
6. Kruse R, Rütten A, Malayeri HR, et al. A novel germline mutation in the hMLH-1 DNA mismatch repair gene in a patient with an isolated cystic sebaceous tumor. J Invest Dermatol 1999;112:117-118.
7. Lynch HT, Fusaro RM. The Muir-Torre syndrome in kindreds with hereditary nonpolyposis colorectal cancer (Lynch syndrome): A classic obligation in preventive medicine. J Am Acad Dermatol 1999;41:797-799.
8. Rothenberg J, Lambert WC, Vail JT, et al. The Muir-Torre syndrome: the significance of a solitary sebaceous tumor. J Am Acad Dermatol 1990;23:638-640.
9. Kruse R, Rütten A, Hosseiry-Malayeri HR, et al. "Second hit" in sebaceous tumors from Muir-Torre patients with germ-line mutations in MSH-2: allele loss is not the preferred mode of inactivation. J Invest Dermatol 2001;116:463-465.
10. Z hang J, Lindroos A, Ollila S, et al. Gene conversion is a frequent mechanism of inactivation of the Wild-Type Allele in cancers from MLH1/ MSH2 deletion carriers. Cancer Res 2006;66: 659-664.
11. Entius ME, Keller JJ, Drillenburg P, et al. Microsatellite Instability and Expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000;6:1784-1789.
12. Machin P, Catasus L, Pons C, et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors for patient of Muir-Torre syndrome. J Cutan Pathol 2002;29:415-420.
13. Marcus VA, Madlensky L, Gryfe R, et al. Immunohistochemistry for hMLH1 and hMSH2: A Practical Test for DNA Mismatch Repair-Deficient Tumors. Am J Surg Pathol 1999;23: 1248-1255.
14. Mathiak M, Rütten A, Mangold E, et al. Loss of DNA Mismatch Repair Proteins in Skin Tumors From Patients with Muir-Torre Syndrome and MSH2 or MLH1 Germline Mutations: Establishment of Immunohistochemical Analysis as a Screening Test. Am J Surg Pathol 2002;26:338-343.
15. Ponti G, Ponz de Leon M, Losi L, et al. Different Phenotypes in Muir-Torre Syndrome: clinical and biomolecular characterization in two Italian families. Br J Dermatol 2005;152:1335-1338.
16. Southey M, Young MA, Whitty J, et al. Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre Syndrome and gives insight its underlying molecular pathogenesis. Am J Surg Pathol 2001;25:936-941.
17. Kruse R, Rütten A, Schweiger N, et al. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol 2003;120:858-864.
18. Marazza G, Masouyé I, Taylor S, et al. An Illustrative Case of Muir-Torre Syndrome. Arch Dermatol 2006;142:1039-1042.
19. Kruse R, Rütten A, Lamberti C, et al. Muir Torre Phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998;63:63-70.
20. Mangold E, Pagenstrecher C, Leister M, et al. A genotype-phenotype correlation in HNPCC: strong predominance of MSH-2 mutations in 41 patients with Muir-Torre Syndrome. J Med Genet 2004;41:567-572.
21. Ponti G, Losi L, Pedroni M, et al. Value of MLH1 and MSH2 Mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 2006;126:2302-2307.
22. Singh R, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol 2008;32:936-942.
23. Popnikolov NK, Gatalica Z, Colome-Grimmer MI, Sánchez RL. Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol 2003;30:178-184.
24. Cesinaro AM, Ubiali A, Sighinolfi P, et al. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol 2007;29:351-358.